Cancer Therapy

U.S. FDA grants IND clearance for eniluracil

Published in Biotech Business Week, December 26th, 2005

Adherex Technologies, Inc., (ADH, AHX) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for eniluracil, which the company in-licensed from GlaxoSmithKline (GSK) in July 2005.

This IND clearance enables Adherex to commence U.S.-based clinical trials of eniluracil, as part of its global development plans.

"This regulatory clearance by the FDA was an important step in our efforts to rapidly develop eniluracil. In less than 4 months, we now have clinical quality drug and have submitted and received regulatory clearance to proceed with our initial clinical trials. We expect these trials...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry